News

The drug, whose proposed brand name is Arxxant, reduced the risk of sustained moderate vision loss by 41% when compared to placebo in patients with moderate to severe,

HGS will retain a 13% equity interest in CoGenesys which has exclusive rights to develop and commercialize biological products based on certain human genes discovered by HGS. CoGenesys

The 12 month study is focused on examining safety as well as efficacy of the drug in patients with paroxysmal nocturnal hemoglobinuria (PNH), an acquired genetic blood disorder

Statistical significance on the primary outcome measure of the trial of change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score was not achieved, however, statistically

These data were presented at the 66th Annual Scientific Sessions of the American Diabetes Association. “These findings are important because they confirm that people who switched from rapid-acting

Additionally, treatment with Januvia improved measures of beta cell function. Beta cells are cells in the pancreas that make and release insulin. The data from the studies were

The FDA has requested additional safety information on Trexima, which may require new studies. Pozen and GSK said that they intend to request a meeting with the FDA

A novel insulin sensitizer, metaglidasen has been shown in a previously conducted phase II trial in patients with diabetes to be well tolerated and to lower blood glucose,

The data, presented at the American Diabetes Association's annual scientific sessions, show that WelChol treatment resulted in a mean 0.5% reduction in A1C versus placebo. Moreover, in patients